Dendritic Cell Immunotherapy for Melanoma

Author(s): Judy C. Peng, Ranjeny Thomas, Keith Dredge

Journal Name: Reviews on Recent Clinical Trials

Volume 1 , Issue 2 , 2006

Become EABM
Become Reviewer


Dendritic cells (DC) are the most potent antigen-presenting cells that initiate T cell-mediated immune responses against cancer. It has been almost a decade since the first trial of DC-based cancer immunotherapy was published. Despite the many clinical trials conducted since, few solid conclusions have been reached, and no specificimmunotherapy has routinely demonstrated meaningful anti-tumour responses. Clinical-grade DC can be obtained from three distinct cell populations in the blood - monocytes, CD34+ progenitors or direct isolation of circulating blood DC. This review discusses the science behind DC-based cancer immunotherapy, with a particular emphasis on the use of monocyte-derived DC in melanoma clinical trials, and the various potential avenues for improvement of patient clinical response rates.

Keywords: Dendritic cells, Cancer immunotherapy, Melanoma, Clinical trials

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [87 - 102]
Pages: 16
DOI: 10.2174/157488706776876517
Price: $65

Article Metrics

PDF: 6